<<
>>

Conclusion

Echocardiography has an important role for HIV patients, allowing the diagnosis of car­diac abnormalities, allowing follow-up and in evaluating the prognosis. In the HAART era, the prevalence and incidence of cardiac abnormalities should be reassessed.

The effect of HAART therapy on the incidence of HIV-related cardiovascular disease and manifestations should be prospectively determined. Prospective studies are needed to fully analyse the impact of HAART ther­apy on the development of cardiac abnor­malities and to evaluate the potential com­plications due to their administration. Echocardiography with the development of new technologies such as myocardial Doppler imaging, strain-rate imaging, three­dimensional and contrast echocardiography, should be useful in this respect.

References

1. Barbaro G (2002) Cardiovascular manifestations of HIV infection. Circulation 106:1420-5

2. Fisher SD, Lipshultz SE (2001) Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann NY Acad Sci 946:13-22

3. Barbaro G (2003) Evolution of the involvement of the cardiovascular system in HIV infection. Adv Cardiol 40:15-22

4. Barbarini G, Barbaro G (2003) Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 17:S46-50

5. Reuter H, Burgess LJ, Doubell AF (2005) Epi­demiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 133:393-399

6. Heidenreich PA, Eisenberg MJ, Kee LL et al (1995) Pericardial effusion in AIDS: incidence and survival. Circulation 92: 3229-3234

7. Chen Y, Brennessel D, Walters J et al (1999) Immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the lit­erature. Am Heart J 137:516-521

8. Pugliese A, Isnardi D, Saini A et al (2000) Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement.

J Infect 40: 282-284

9. Roy CL, Minor MA, Brookhart MA, Choudhry NK (2007) Does this patient with a pericardial effusion have cardiac tamponade? JAMA 297:1810-1818

10. Gowda RM, Khan IA, Sacchi TJ, Vasavada BC (2003) Cardiac tamponade in acquired immun-

odeficiency syndrome. Int J Cardiol 88:313-314

11. Iacobellis G, Pellicelli AM, Sharma AM et al (2007)Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Car­diol 99:1470-1472

12. Pinamonti B, Alberti E, Cigalotto A et al (1988) Echocardiographic findings in myocarditis. Am J Cardiol 62:285-289

13. Camerini F, Bussani R, Lenarda D et al (1991) Clinical aspects and haemodynamics in the fol­low-up of dilated cardiomyopathy and myocardi­tis. Eur Heart J 12(Suppl D):193-196

14. Hiramitsu S, Morimoto S, Kato S et al (2001) Transient ventricular wall thickening in acute myocarditis: a serial echocardiographic and histopathologic study. Jpn Circ 65:863-866

15. Lieback E, Hardouin I, Meyer R et al (1996) Clinical value of echocardiographic tissue char­acterization in the diagnosis of myocarditis. Eur Heart J 17:135-142

16. Felker GM, Boehmer JP, Hruban RH et al (2000) Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36:227-232

17. Mendes LA, Picard MH, Dec GW et al (1999) Ven­tricular remodeling in active myocarditis: my­ocarditis treatment trial. Am Heart J 138:303-308

18. Thuny F, Avierinos JF, Jop B et al (2006) Images in cardiovascular medicine: massive biventricu­lar thrombosis as a consequence of myocarditis: findings from 2-dimensional and real-time 3­dimensional echocardiography. Circulation 113:e932-933

19. Mendes LA, Dec GW, Picard MH et al (1994) Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. Am Heart J 128:301-307

20. Swedberg K, Cleland J, Dargie H et al (2005) Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26:1115-1140

21.

Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G (1998) Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV­positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 339:1093-1099

22. Cardoso JS, Moura B, Martins L et al (1998) Left ventricular dysfunction in human immunodefi­ciency virus (HIV) infected patients. Int J Car­diol 63:37-45

23. Longo-Mbenza B, Seghers KV, Phuati M et al (1998) Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 64:63-73

24. Twagirumukiza M, Nkeramihigo E, Seminega B et al (2007) Prevalence of dilated cardiomyopa­thy in HIV-infected African patients not receiv­ing HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 5:129-137

25. Brown DL, Sather S, Cheitlin MD (1993)Reversible cardiac dysfunction associat­ed with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient. Am Heart J 125:1439-1441

26. Galia N, Torbicki A, Barst R et al (2004) Guide­lines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diag­nosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardi­ology. Eur Heart J 25:2243-2278

27. Opravil M, Pechere M, Speich R et al (1997) HIV-associated primary pulmonary hyperten­sion: a case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155:990-995

28. Mesa RA, Edell ES, Dunn WF, Edwards WD (1988) Human immunodeficiency virus infec­tion and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 73:37-45

29. Petitpretz P, Brenot F, Azarian R et al (1994) Pul­monary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circula­tion 89:2722-2727

30. Ehrenreich H, Rieckmann P, Sinowatz F et al (1993) Potent stimulation of monocytic endothe- lin-1 production by HIV-1 glycoprotein 120.

J Immunol 150:4601-4609

31. Humbert M, Monti G, Fartoukh M et al (1998) Platelet-derived growth factor expression in pri­mary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554-559

32. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA (2000) HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 118:1133-1141

33. Zuber JP, Calmy A, Evison JM et al; Swiss HIV Cohort Study Group (2004) Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associat­ed with antiretroviral therapy. Clin Infect Dis 38:1178-1185

34. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocar­diography’s Guidelines and Standards Commit­tee and the Chamber Quantification. J Am Soc Echocardiogr 18:1440-1463

35. Martinez-Garcia T, Sobrino JM, Pujol E et al (2000) Ventricular mass and diastolic function in patients infected by the humanimmuno defi-

ciency virus. Heart 84:620-624

36. Coudray N, de Zuttere D, Force G et al (1995) Ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: an echocardiographic study. Eur Heart J 16:61-67

37. Samaan SA, Foster A, Raizada V et al (1995) Myocardial atrophy in acquired immunodefi­ciency syndrome: associated wasting. Am Heart J 130:823-827

38. Meng Q, Lima JA, Lai H, Vlahov D et al (2002) HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr 30:306-310

39. Losa JE, Miro JM, Del Rio A et al (2003) Endo­carditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literature. Clin Microbiol Infect 9:45-54

40. De Rosa FG, Cicalini S, Canta F et al (2007) Infective endocarditis in intravenous drug users from Italy: the increasing importance in HIV- infected patients. Infection 35:154-160

41.

Gebo KA, Burkey MD, Lucas GM et al (2006) Incidence of, risk factors for, clinical presenta­tion, and 1-year outcomes of infective endo­carditis in an urban HIV cohort. J Acquir Immune Defic Syndr 43:426-432

42. Valencia E, Miro J (2004) Endocarditis in the setting of HIV infection. AIDS Rev 6:97-106

43. Horstkotte D, Follath F, Gutschik E et al (2004) Guidelines on prevention, diagnosis and treat­ment of infective endocarditis executive sum­mary: the task force on infective endocarditis of the European society of cardiology. Eur Heart J 25:267-276

44. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study (2007) AIDS-related cancer and severity of immuno­suppression in persons with AIDS. J Natl Cancer Inst 99:962-972

45. Khan NU, Ahmed S, Wagner P et al (2004)Car- diac involvement in non-Hodgkin’s lymphoma: with and without HIV infection. Int J Cardio- vasc Imaging 20:477-481

46. Iwahashi N, Nakatani S, Kakuchi H et al (2005) Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome. Circ J 69:243-245

<< | >>
Source: Barbaro Giuseppe, Boccara Franc (eds.). Cardiovascular Disease in AIDS. 2nd edition. — Springer,2009. — 169 p.. 2009
More medical literature on Medic.Studio

More on the topic Conclusion: